In the BTK inhibitor–naive setting, the BTK degrader tacabrutideg was safe with antitumor activity in CLL and other B-cell malignancies #EHA2026 #leusm #oncology Read more on cohort 1f of the phase 1 CaDAnCe-101 trial: www.onclive.com/view/tacabru...

LB2501, an off-the-shelf in vivo dual-target CAR T-cell therapy, produced a 100% ORR at dose level 2 across DLBCL, MCL, and follicular lymphoma. #EHA2026 #lymsm #hematology www.onclive.com/view/in-vivo...

WATCH: Mark D. Tyson, II, MD, MPH of @mayocliniccancer.bsky.social discusses data from a real-world study of blue light cystoscopy in high-risk NMIBC. #oncology #NMIBC #bladdercancer www.onclive.com/view/dr-tyso...

Subcutaneous blinatumomab led to high response rates across 2 dosing regimens in heavily pretreated patients with relapsed/refractory, Ph-positive B-ALL in a phase 1/2 trial #EHA2026 #leusm #oncology Dive into the data: www.onclive.com/view/subcuta...

WATCH: Benjamin Croll, MD, of @foxchasecancer.bsky.social discusses research focused on understanding response to systemic therapy in RCC. #oncology #RCC #kcsm www.onclive.com/view/dr-crol...

Real-world data from the CIBMTR registry at #EHA2026 reinforce the impact of liso-cel in relapsed/refractory #MCL. ✅ ORR of 89% and CR rate of 79% ✅ Median DOR, PFS, and OS not reached ✅ Safety profile consistent with pivotal trial results Learn more: www.onclive.com/view/real-wo...

Updated ROCK-1 data at #EHA2026 show that rocbrutinib continues to deliver activity in R/R #MCL previously treated w/ a covalent BTK inhibitor. #lymsm ✅ ORR of 63.9%, including a 23.0% CR rate ✅ Median DOR of 16.46 months ✅ Median OS NR at 23.36 months of follow-up onclive.com/view/rocbrut...

🦴🚨 The FDA has accepted the BLA for ozekibart (INBRX-109) in patients with unresectable or metastatic conventional chondrosarcoma, marking a major regulatory milestone in a disease with no approved systemic therapies. Read more ➡️ www.onclive.com/view/fda-acc... #Sarcoma #Chondrosarcoma #Oncology

The combination of cadonilimab plus axitinib demonstrated promising efficacy and a manageable safety profile as frontline therapy for advanced non–clear cell RCC. Read more ➡️ www.onclive.com/view/cadonil... #KidneyCancer #RCC #nccRCC #GUonc #Immunotherapy #kcsm #Oncology

Tuspetinib/venetoclax/azacitidine produced high CR and MRD-negativity rates across molecular subgroups of older or unfit patients newly diagnosed AML. #EHA2026 #leusm #hematology www.onclive.com/view/tuspeti...

Fixed-duration pirtobrutinib plus venetoclax and rituximab reduced the risk of progression or death by 45% in previously treated CLL. @drmdavids.bsky.social @danafarber.bsky.social @harvardmed.bsky.social #EHA2026 #leusm #lymsm Read the full story on our site! www.onclive.com/view/fixed-d...

WATCH: Peter Voorhees, MD, discusses efficacy data for talquetamab plus daratumumab with or without pomalidomide from MonumenTAL-3. @wakeforestmed.bsky.social #EHA2026 #mmsm #hematology www.onclive.com/view/dr-voor...

WATCH: Stephan Stilgenbauer, MD, discusses safety considerations for BGB-16673 and where its development is headed in chronic lymphocytic leukemia. #EHA2026 #leusm #hematology www.onclive.com/view/dr-stil...

Update: #EHA2026: Long-term results from KOMET-007 trial highlight the potential of ziftomenib plus 7+3 in newly diagnosed #AML w/ NPM1 mutations or KMT2A rearrangements. The data support ongoing phase 3 evaluation of this menin inhibitor–based approach. Read more: www.onclive.com/view/ziftome...

Phase 1 data showed that INCA033989 produced rapid and durable responses as monotherapy and in a combination regimen in CALR-mutated myelofibrosis. @gstt-nhs.bsky.social #EHA2026 #hematology #oncology www.onclive.com/view/inca033...

The type II JAK2 inhibitor AJ1-11095 produced SVRs, deep symptom responses, and mutation VAF reductions in type I JAK inhibitor–exposed myelofibrosis. #EHA2026 #hematology #oncology www.onclive.com/view/aj1-110...

EPCORE DLBCL-1: #EHA2026: Epcoritamab outperformed investigator’s choice of CIT in relapsed/refractory large B-cell lymphoma, improving PFS and delivering durable complete responses. ✅ Higher CR rate ✅ More durable remissions ✅ 27% PFS at 3 years Read more: www.onclive.com/view/epcorit...

📢 #EHA26: Talquetamab-based combinations delivered impressive results in R/R #myeloma. ✅ Up to 72% reduction in risk of progression or death ✅ Higher CR and MRD-negative CR rates ✅ Clinically meaningful OS improvement trends www.onclive.com/view/monumen...

🩸 #EHA2026 update: A first-in-class, switchable allogeneic #CAR_T therapy showed encouraging activity in R/R #AML. ✅ CR/CRh responses, including MRD-negative remissions ✅ No GVHD or ICANS reported ✅ Phase 1b enrollment underway Read more: www.onclive.com/view/switcha...

Back in 2025, we learned that the INDEPENDENCE trial narrowly missed its primary end point. At #EHA2026, investigators dived into the full data. Read more on the phase 3 findings for luspatercept in myelofibrosis-associated anemia #mpnsm #oncology www.onclive.com/view/luspate...

Topline results from the phase 3 LAGOON trial showed that lurbinectedin, alone or in combination with irinotecan, missed the primary OS end point in patients with relapsed small cell lung cancer. 📊 Read more ➡️ www.onclive.com/view/topline... #LungCancer #SCLC #ThoracicOncology #lcsm #Oncology

WATCH: Jiong Wu, MD, PhD, discusses the significance of studying iza-bren in a phase 3 setting in unresectable, locally advanced or metastatic TNBC. @ascocancer.bsky.social #ASCO26 #bcsm #oncology www.onclive.com/view/dr-wu-o...

A cytogenetic subgroup analysis of the CARTITUDE-4 trial showed a partial response or better to bridging therapy led to improved survival outcomes in patients with lenalidomide-refractory multiple myeloma treated with cilta-cel #mmsm #oncology #EHA2026 www.onclive.com/view/cartitu...

EPCORE FL-1 showed that epcoritamab/lenalidomide/rituximab yielded superior efficacy vs lenalidomide/rituximab across follicular lymphoma populations. #EHA2026 #lymsm #hematology www.onclive.com/view/epcorit...

Azacitidine plus venetoclax and ivosidenib produced robust responses and induced high rates of MRD negativity in IDH1-mutated newly diagnosed AML. @mdanderson.bsky.social #EHA2026 #leusm #hematology www.onclive.com/view/azaciti...

WATCH: Mark Tyson, MD, of @mayocliniccancer.bsky.social discusses efficacy data with TARA-002 in patients with BCG-naive high-grade non–muscle-invasive bladder cancer. www.onclive.com/view/dr-tyso... #oncology #medtwitter #NMIBC #AUA26

🧬 Brenetafusp in advanced melanoma. Daniel Olson, MD, of @uchicagocancer.bsky.social, discusses updated phase 1 data from #ASCO26 @ascocancer.bsky.social: ✅ DCR: 52%–67% depending on dose ✅ Median OS: 14.3 months ✅ CRS attenuates with step-up dosing #melsm www.onclive.com/view/dr-olso...

🔬Early clinical data show that in vivo CAR T-cell therapy generated meaningful responses and MRD negativity in patients with relapsed/refractory multiple myeloma. 📊 Read more ➡️ www.onclive.com/view/in-vivo... #MultipleMyeloma #CAR-T #CellTherapy #Immunotherapy #HemeOnc #Oncology #EHA26

Marwan G. Fakih, MD, of @cityofhope.bsky.social discusses how updated OS data from POD1UM-303 cement frontline retifanlimab plus chemotherapy as the standard of care in advanced SCAC. Read more: www.onclive.com/view/retifan... #oncology #SCAC

Check out our recap of the episodes of OncLive On Air that aired in May 2026. @mpishvaian.bsky.social @bidmc-cancercenter.bsky.social @mskcancercenter.bsky.social @mdanderson.bsky.social @danafarber.bsky.social @ohsuknight.bsky.social #oncology #hematology www.onclive.com/view/revisit...

🚨 The FDA has granted Priority Review to an adjuvant regimen of atezolizumab plus chemotherapy for patients with stage III dMMR colon cancer, following data from the phase 3 ATOMIC trial. 🧬📊 Read more ➡️ www.onclive.com/view/fda-gra... #ColorectalCancer #ColonCancer #GIonc #dMMR #MSIH #Oncology

WATCH: Elena Elimova, MD, of @pmresearch-uhn.bsky.social, discusses data from a HERIZON-GEA-01 PD-L1 subgroup analysis in HER2-positive gastroesophageal adenocarcinoma presented at @ascocancer.bsky.social #ASCO26 #oncology www.onclive.com/view/dr-elim...

WATCH: Matthew Galsky, MD, of @mountsinainyc.bsky.social discusses the present and future use of biomarkers in bladder cancer. #oncology #medtwitter #bladdercancer www.onclive.com/view/dr-gals...

WATCH: Brad Haverkos, MD, of @cuanschutz.bsky.social outlines key management strategies and considerations for mogamulizumab-associated rash in patients with cutaneous T-cell lymphoma #lymsm #oncology www.onclive.com/view/dr-have...

Megan Kruse, MD, of @clevelandclinic.bsky.social breaks down the evolving role of oral SERDs in HR+ breast cancer and key ADC considerations in TNBC #bcsm #oncology www.onclive.com/view/targete...

⚡Panitumumab-based regimens achieved high response rates in heavily pretreated renal medullary carcinoma (RMC), highlighting a potential new therapeutic avenue in a disease with historically poor outcomes. 📊 Read more ➡️ www.onclive.com/view/panitum... #Kcsm #GUonc #ASCO26 #Oncology

☢️ The FDA has approved a generic Ga-68 PSMA-11 radiodiagnostic, adding another commercially available option for PSMA-targeted PET imaging in patients with prostate cancer. 🧬📊 Read more ➡️ www.onclive.com/view/generic... #ProstateCancer #GUonc #PSMA #PETImaging #PrecisionOncology #Oncology

Curiosity, failure, and unexpected tenderness helped fuel @drcamidge.bsky.social in his career in medicine, and, later, his journey as a patient #lcsm #oncology Read more: www.onclive.com/view/from-to...

The 2026 EHA Congress is just a day away. To prep you for the top multiple myeloma data to watch, Joshua Richter, MD, previews the key presentations set to take the stage in Sweden #EHA2026 #mmsm #oncology Sign up and watch our full video preview podcast now: www.onclive.com/view/preview...

WATCH: Sonali Smith, MD, of @uchicagocancer.bsky.social, shares implications of data from the phase 3 frontMIND trial evaluating frontline tafasitamab plus lenalidomide/R-CHOP in high-risk DLBCL #lymsm #oncology www.onclive.com/view/dr-smit...

🎙️ Which GU cancer studies from #ASCO26 will have the biggest impact on clinical practice? From advances in prostate and bladder cancer to evolving treatment paradigms across GU malignancies, these thought leaders highlight the meeting's key findings. Read more ➡️ www.onclive.com/view/gu-canc...

Catch up on May's key pipeline updates across GI cancers with OncLive's Regulatory Rewind! Access the full round-up by signing up here: www.onclive.com/view/may-s-g... #Oncology #FDAApproval #crcsm #oncology

🤖🧬 An AI-powered atlas of tertiary lymphoid structures is providing new insights into their role as prognostic and response biomarkers across cancer types, potentially advancing patient stratification and precision immuno-oncology. @mdanderson.bsky.social Read more ➡️ www.onclive.com/view/ai-powe...

The phase 3 KEYNOTE-D46 trial evaluating sacituzumab govitecan plus pembrolizumab in patients with PD-L1–high advanced NSCLC has been discontinued. 📊 Read more ➡️ www.onclive.com/view/keynote... #LungCancer #NSCLC #Immunotherapy #ADC #ClinicalTrials #Oncology

Nan Chen, MD, discusses ADC-associated toxicity management in breast cancer, as well as the evolving role of oral SERDs in ER-positive disease. @uchicagomedicine.bsky.social #bcsm #oncology www.onclive.com/view/dr-chen...

WATCH: Raj Singh, MD, highlights brain cancer radiation strategies and unmet needs for #WorldBrainTumorDay. #btsm #oncology See our Brain Cancer page for more insights! www.onclive.com/clinical/bra...

WATCH: In observance of World Brain Tumor Day, Raj Singh, MD, highlights the importance of multidisciplinary collaboration in brain cancer management. #btsm #oncology www.onclive.com/view/dr-sing...

💉 The EU has approved subcutaneous isatuximab delivered via an OBI, offering a streamlined alternative to IV administration while maintaining the efficacy and safety profile established with the anti-CD38 antibody. 📊 Read more ➡️ www.onclive.com/view/subcuta... #MultipleMyeloma #Oncology

Phase 1/2 data show that the PRMT5 inhibitor vopimetostat plus daraxonrasib yielded a 92% ORR in MTAP-deleted, RAS-mutant metastatic pancreatic cancer. @danafarber.bsky.social #pancsm #oncology www.onclive.com/view/vopimet...

WATCH: Heather Leeper of @uchicagocancer.bsky.social discusses ideal survivorship care for geriatric patients with brain cancer. #oncology #braincancer #braintumour #braintumourawareness #WorldBrainTumorDay www.onclive.com/view/dr-leep...